system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Animals, Antineoplastic Agents, Cell Line, Tumor, Cell Movement, Cell Survival, Cell Transformation, Neoplastic, Disease Progression, Gene Expression Regulation, Neoplastic, Histones, Humans, Male, Methylation, Mice, Mice, SCID, Neoplastic Stem Cells, Polycomb-Group Proteins, Prostatic Neoplasms, RNA, Messenger, Repressor Proteins, Spheroids, Cellular, Tumor Cells, Cultured, Xenograft Model Antitumor Assays.
user
Does pharmacologic disruption of Polycomb Repressive Complex 2 inhibit tumorigenicity and tumor progression in prostate cancer? Context: Polycomb repressive complex 2 (PRC2) mediates gene silencing through histone H3K27 methylation. PRC2 components are over-expressed in metastatic prostate cancer (PC), and are required for cancer stem cell (CSC) self-renewal. 3-Dezaneplanocin-A (DZNeP) is an inhibitor of PRC2 with broad anticancer activity. we investigated the effects of DZNeP on cell proliferation, tumorigenicity and invasive potential of PC cell lines (LNCaP and DU145). Exploring GEO and Oncomine databases, we found that specific PRC2 genes (EED, EZH2, SUZ12) predict poor prognosis in PC. Non-toxic DZNeP concentrations completely eradicated LNCaP and DU145 prostatosphere formation, and significantly reduced the expression of CSC markers. At comparable doses, other epigenetic drugs were not able to eradicate CSCs. DZNeP was also able to reduce PC cell invasion. Cells pre-treated with DZNeP were significantly less tumorigenic (LNCaP) and formed smaller tumors (DU145) in immunocompromised mice.
assistant
DZNeP is effective both in vitro and in vivo against PC cells. DZNeP antitumor activity is in part mediated by inhibition of CSC tumorigenic potential. Final Decision: yes